fda warning compounded tirzepatide safety Side Effects of Tirzepatide: Complete Guide Congress Introduces SAFE Drugs Act

Tommasini-Ghelfi, S., Murnan, K., Kouri, F

Repair and regeneration connections position GH/IGF-1 axis support as relevant to tissue healing, potentially complementing direct-acting repair peptides

[14] BCBS Massachusetts explicitly excludes coverage for both obesity and sleep apnea starting 2026

Back Bloom, A (11 Nov 2024) 'Weight loss injections and cancer: 6 questions, answered', MD Anderson Cancer Center

"In the SURPASS-1 results, tirzepatide led to significant improvements across all primary and key secondary endpoints with clinically meaningful A1C reductions and robust weight loss among study participants, who had a relatively short duration of type 2 diabetes." Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that integrates the actions of the GIP and GLP-1 incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes